1. Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays
- Author
-
Kevin J. Clerkin, MD, MSc, Sarah B. See, PhD, Maryjane A. Farr, MD, MSc, Susan W. Restaino, MD, Geo Serban, PhD, Farhana Latif, MD, Lingzhi Li, Paolo C. Colombo, MD, George Vlad, PhD, Bryan Ray, PhD, Elena R. Vasilescu, MD, and Emmanuel Zorn, PhD
- Subjects
Surgery ,RD1-811 - Abstract
Background. Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ grafts. The 2 main kits to detect anti-HLA Ab in patient serum are commercialized by Immucor and One Lambda/ThermoFisher. We sought to compare the performance of both platforms. Methods. Background-adjusted mean fluorescence intensity (MFI) values were used from both platforms to compare sera collected from 125 pretransplant and posttransplant heart and lung transplant recipients. Results. Most HLA class I (94.5%) and HLA class II (89%) Abs with moderate to high MFI titer (≥4000) were detected by both assays. A modest correlation was observed between MFI values obtained from the 2 assays for both class I (r = 0.3, r2 = 0.09, P < 0.0001) and class II Ab (r = 0.707, r2 = 0.5, P < 0.0001). Both assays detected anti–class I and II Ab that the other did not; however, no specific HLA allele was detected preferentially by either of the 2 assays. For a limited number of discrepant sera, dilution resulted in comparable reactivity profiles between the 2 platforms. Conclusions. Immucor and One Lambda/ThermoFisher assays have a similar, albeit nonidentical, ability to detect anti-HLA Ab. Although the correlation between the assays was present, significant variances exist, some of which can be explained by a dilution-sensitive “prozone” effect.
- Published
- 2017
- Full Text
- View/download PDF